BUB
ALXN

BBVA USA Bancshares’s Alexion Pharmaceuticals ALXN Stock Holding History

BBVA USA Bancshares’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$236K Sell
1,543
-842
-35% -$130K 0.01% 511
2020
Q4 		$372K Sell
2,385
-56
-2% -$7.2K 0.02% 434
2020
Q3 		$278K Sell
2,441
-188
-7% -$20.3K 0.02% 454
2020
Q2 		$295K Buy
2,629
+188
+8% +$20K 0.02% 448
2020
Q1 		$219K Sell
2,441
-295
-11% -$29K 0.02% 447
2019
Q4 		$296K Buy
+2,736
New +$293K 0.02% 452
2019
Q3 		– Sell
-2,086
Closed -$273K – 518
2019
Q2 		$273K Buy
2,086
+349
+20% +$45K 0.02% 466
2019
Q1 		$235K Buy
+1,737
New +$216K 0.01% 476
2018
Q4 		– Sell
-1,570
Closed -$218K – 542
2018
Q3 		$218K Buy
+1,570
New +$197K 0.01% 512
2017
Q1 		– Sell
-1,869
Closed -$229K – 558
2016
Q4 		$229K Sell
1,869
-414
-18% -$50.7K 0.02% 509
2016
Q3 		$280K Sell
2,283
-132
-5% -$17K 0.02% 469
2016
Q2 		$282K Sell
2,415
-544
-18% -$77.2K 0.02% 448
2016
Q1 		$412K Sell
2,959
-519
-15% -$76.2K 0.03% 382
2015
Q4 		$664K Buy
3,478
+601
+21% +$105K 0.05% 298
2015
Q3 		$450K Buy
2,877
+1,080
+60% +$197K 0.04% 335
2015
Q2 		$325K Buy
+1,797
New +$310K 0.02% 418

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBVA USA Bancshares's ALXN Position: Q1 2021 in Review

BBVA USA Bancshares reduced its Alexion Pharmaceuticals (ALXN) stake by 35% in Q1 2021, selling an estimated $130K and leaving 1,543 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #511.

BBVA USA Bancshares first reported a position in ALXN in Q2 2015 and has held it in 16 quarters since. The position peaked at $664K in Q4 2015. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • BBVA USA Bancshares held 1,543 shares of Alexion Pharmaceuticals worth $236K as of Q1 2021.
  • BBVA USA Bancshares sold 842 Alexion Pharmaceuticals shares in Q1 2021, an estimated $130K.
  • Alexion Pharmaceuticals made up 0.01% of BBVA USA Bancshares's portfolio in Q1 2021, its #511 holding.
  • BBVA USA Bancshares first reported a position in Alexion Pharmaceuticals in Q2 2015 and has held it in 16 quarters since.
  • BBVA USA Bancshares's Alexion Pharmaceuticals position peaked at $664K in Q4 2015.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on BBVA USA Bancshares's 13F filing for Q1 2021, filed 23 Apr 2021.